KRAS and cancer: BI-1701963, an improved version of BI-3406, is currently in three phase I trials to determine the safety, tolerability, and pharmacokinetic parameters of BI-1701963 monotherapy or in combination with trametinib, BI-3011441 (a MEK inhibitor), or irinotecan in patients with KRAS-mutated cancers (NCT04111458, NCT04835714, and NCT04627142).